Henry Ji, Sorrento CEO (Scilex Pharmaceuticals)
May 19, 2020 11:11 AM EDTUpdated May 20, 07:25 AM
R&D
Coronavirus

How a Cal­i­for­nia biotech briefly tripled its val­ue by hyp­ing a Covid-19 ‘cure’

Jason Mast

Editor

Last week, a Cal­i­for­nia biotech called Sor­ren­to Ther­a­peu­tics emailed re­porters about the dis­cov­ery of an “ex­cep­tion­al­ly po­tent an­ti­body” for Covid-19. Then the CEO, Hen­ry Ji …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times